Clinical trials testing paxalisib in DMG, both as monotherapy (NCT03696355) and in combination with ONC201 (NCT05009992), have reported PI3K inhibitor-related side effects, particularly mucositis, rash, colitis and hyperglycemia. This evidence concerns the gene PIK3CD and Hyperglycemia.